EBV LMP-2A (15F9) Antibody sc-101315 from Santa Cruz Biotechnology, Inc.

Product Specs
ItemEBV LMP-2A (15F9) Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $316.00Supplier Page View Company Product Page
Catalog Numbersc-101315
Antibody TypePrimary Antibodies
Quantity200 µg/ml
Clone15F9
ReactivityEBV
ApplicationsWB, IF, IHC(P)
Conjugate/TagUnconjugated
FormatPurified
ClonalityMonoclonal
Hostrat
IsotypeIgG1
TargetEBV LMP-2A

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphomaTranslational OncologyFebruary 1, 2024Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyangmembrane was then blocked with 3 % BSA at room temperature for 2 h. Primary antibodies [rat anti-LMP2A (sc-101315, Santa Cruz Biotechnology), mouse anti-LMP1 (sc-71023, Santa Cruz Biotechnology), sheep anti-EBNA3A

(2) Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximabFrontiers in immunologyJanuary 1, 2023Tischer-Zimmermann S, Bonifacius A, Santamorena MM, Mausberg P, Stoll S, Döring M, Kalinke U, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.

(3) LMP2A inhibits the expression of KLF5 through the mTORC1 pathway in EBV-associated gastric carcinomaVirus researchJuly 2, 2022Liu D, Shi D, Xu L, Sun L, Liu S, Luo B.

(4) LMP2A suppresses the role of AHR pathway through ERK signal pathway in EBV-associated gastric cancerVirus researchMay 1, 2021Jiang Y, Xiao H, Sun L, Zhang Y, Liu S, Luo B.

(5) EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized micePLoS pathogensJune 1, 2020Li C, Romero-Masters JC, Huebner S, Ohashi M, Hayes M, Bristol JA, Nelson SE, Eichelberg MR, Van Sciver N, Ranheim EA, et al.Inc. ab-78113 WB LMP2A Santa Cruz Biotechnology sc-101314 WB LMP2A Santa Cruz Biotechnology sc-101315 IHC BZLF1 Santa Cruz Biotechnology sc-53904 IHC&WB BZLF1 Santa Cruz Biotechnology sc-17503 IHC CD3 DakoCytomation A0452 IHC CD4 Leica

(6) Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycleThe Journal of pathologyAugust 1, 2013Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG.

(7) An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse modelJournal of virologyAugust 1, 2012Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML, Kenney SC.

(8) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyBloodNovember 11, 2010Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, et al.

Be the First to Write a Review!

EBV LMP-2A (15F9) Antibody

EBV LMP-2A (15F9) Antibody from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (8)

Reviews

EBV LMP-2A (15F9) Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map